cisplatin + dulanermin + vinorelbine

This is a combination regimen consisting of three agents: - **Cisplatin** is a platinum-based chemotherapy drug that forms DNA crosslinks, leading to apoptosis (cell death) in rapidly dividing cells. - **Dulanermin** (also known as recombinant human Apo2L/TRAIL) is an experimental biologic agent that induces apoptosis by binding to death receptors DR4 and DR5 on tumor cells, activating the extrinsic apoptotic pathway. - **Vinorelbine** is a vinca alkaloid chemotherapy drug that inhibits microtubule assembly, thereby blocking mitosis and cell division[1][2][3][6]. This combination has been investigated primarily for the treatment of non-small cell lung cancer (NSCLC), leveraging complementary mechanisms of action to enhance antitumor efficacy.